Ikena Oncology Inc. (IKNA) - Net Sales Margin

Ikena Oncology - graphic logo of issuer IKNA

The absence of dividends for Ikena Oncology, Inc. (IKNA) is driven by the risk of clinical trial failure and a shortage of research funding. The return on sales serves as a confidence indicator, where the value 0.00 describes the current profitability level. Meanwhile, a stable cash reserve ensures coverage of R&D expenses, while patent protection for inhibitors and strict FDA oversight create significant barriers to entry for new players.

IKNA: Ikena Oncology Net Profit Rate 07/04/2022 - 08/09/2025

Comprehensive metric breakdowns and analytics for ikenaoncology.com (IKNA)

- market value and analyst target forecast:
Basic company analysis:Ikena Oncology, Inc.
Manufactured product of Ikena Oncology, Inc.

The efficiency of targeted drug development at Ikena Oncology, Inc. (IKNA) is reflected in the dynamics of its operating net sales margin. This indicator is calculated as the ratio of final profit to total revenue, measuring the share of net income in every dollar earned. The metric demonstrates management's ability to optimize clinical trial costs. For a biotech company, this is a critical marker of the transition toward drug commercialization. Investors should evaluate the stability of this figure as a guarantee of future financial sustainability.

Analysis of competing companies

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Net Margin|Net Margin Citius Oncology, Inc. CTOR|HURA - Return on Sales by Net Profit|protaratx.com - Net Sales Margin|FATE - Net Sales Margin|WHWK: Net Sales Margin|TScan Therapeutics (TCRX) - Net Sales Margin|Net Margin Champions Oncology|Net Margin XBIT|Net Sales Margin CVM|Return on Sales by Net Profit OS Therapies Inc. OSTX|Net Margin Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Net Margin|ANL - Net Margin|Net Margin verupharma.com|TPST: Net Sales Margin|XLO - Company Sales Margin|Net Margin Renovaro|Net Sales Margin muraloncology.com|Net Sales Margin KAPA|Company Sales Margin OnKure Therapeutics, Inc.|Net Sales Margin GDTC (w2.cytomed.sg)|CRIS - Return on Sales by Net Profit|Apollomics - Net Sales Margin|Tharimmune Corp (THAR) - Return on Sales by Net Profit|ADVB: Net Sales Margin|Return on Sales by Net Profit Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Net Sales Margin|Net Return on Sales SBFM (Sunshine Biopharma)|Net Margin Xenetic Bio (XBIO)|Net Margin SLRX (Salarius Pharma)|Kitov Pharma - Return on Sales by Net Profit|American Oncology Network (AONC) - Net Margin|BeiGene - Net Sales Margin|Checkpoint Therapeutics, Inc. (CKPT) - Return on Sales by Net Profit|ELEV (Elevation Oncology, Inc.) - Return on Sales by Net Profit|iCAD Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)